Alogabat

Alogabat
Clinical data
Other namesGABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773
Routes of
administration
Oral
Drug classα5 subunit-containing GABAA receptor positive allosteric modulator
Identifiers
  • 6-[[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC21H23N5O4
Molar mass409.446 g·mol−1
3D model (JSmol)
  • CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C
  • InChI=1S/C21H23N5O4/c1-13-3-4-15(11-22-13)20-17(14(2)30-26-20)12-29-19-6-5-18(24-25-19)21(27)23-16-7-9-28-10-8-16/h3-6,11,16H,7-10,12H2,1-2H3,(H,23,27)
  • Key:ACZCJTHHWMBFKC-UHFFFAOYSA-N

Alogabat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome. It is taken by mouth.

As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome. It is under development by Roche.

See also